Figure 2

NOXA protein expression decreases post-NAC in invasive breast cancer samples. (A) Representative immunohistochemistry images of significant decrease in the overall expression of NOXA protein in a case of breast Invasive Ductal Carcinomas (IDC), luminal B (HER2-\PR-\ER +), stage III. (B) Immunofluorescence (IF) images of NOXA protein in a case of breast IDC, luminal A (HER2-\PR + \ER +), stage I,  showing significant decline in NOXA overall expression post-NAC. DAPI was used as a nuclear marker. Images were acquired at × 100. (C) The overall decrease of NOXA protein expression in our 55 samples of invasive breast cancer that were collected pre- and post- NAC. Blue lines indicate the decrease in NOXA protein expression post-NAC, while orange lines indicate the increase in NOXA protein expression following NAC and gray lines indicate that no change in expression was recorded. Statistical differences were calculated using Mann–Whitney and Wilcoxon signed rank tests. Ns: not significant, *: p value < 0.05; **: p value < 0.01; ***: p value < 0.001; ****: p value < 0.0001. NAC: neoadjuvant chemotherapy.